No Data
Painful Week for Retail Investors Invested in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) After 24% Drop, Institutions Also Suffered Losses
IMMUNEONCO-B (01541) received a filing notice from the China Securities Regulatory Commission regarding the implementation of the company's full circulation of H shares.
IMMUNEONCO-B (01541) announced that the company has recently received the notice from the China Securities Regulatory Commission regarding the implementation of the full circulation of H shares...
IMMUNEONCO-B (01541.HK) will hold a Board of Directors meeting on March 25 to consider and approve the annual performance.
Gelonghui March 13, IMMUNEONCO-B (01541.HK) announced that the Board of Directors will hold a meeting on Tuesday, March 25, 2025, to consider and approve the performance of the company and its subsidiaries for the year ended December 31, 2024, and its publication, and to consider the proposal for the distribution of a final dividend (if any).
IMMUNEONCO-B: DATE OF BOARD MEETING
The adjustment of the Hong Kong Stock Connect securities list has led to a widespread decline in the stock prices of the excluded companies.
Jinwu Finance News | The Shanghai Stock Exchange and the Shenzhen Stock Exchange each issued announcements stating that due to the periodic adjustments of the constituent stocks of the Hang Seng Composite LargeCap Index, the MidCap Index, and the SmallCap Index, the corresponding list of securities included and excluded from the Hong Kong Stock Connect trading range will be adjusted. This adjustment will take effect on March 10. After the adjustment takes effect, the stock prices of individual stocks removed from the Hong Kong Stock Connect list generally show a downward trend. Among them, KINGKEY FIN INT (01468) performed the weakest, with the current stock price down 32%, reported at HKD 0.255. In addition, IMMUNEONCO-B (01541) stock price fell by 11.58%; LAEKNA-B (021
Express News | ImmuneOnco Biopharmaceuticals Shanghai - Approval From Nmpa China for Clinical Trial of Imm01 (Timdarpacept)
